Active substance
Bemiparin
- SFDA 5
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| HIBOR 10000 I.U.- 0.4 ML PREFILLED SYRINGE | 10000 IU | Solution for injection in pre-filled syringe · Parenteral use | 2 Pre-filled syringe | SAR 113.30 | Biological · Prescription | Hikma Pharmaceuticals PLC | Valid |
| HIBOR 2500 I.U. - 0.2 ML PREFILLED SYRINGE | 2500 IU | Solution for injection in pre-filled syringe · Parenteral use | 2 Pre-filled syringe | SAR 28.30 | Biological · Prescription | Hikma Pharmaceuticals PLC | Valid |
| HIBOR 3500 I.U. - 0.2 ML PREFILLED SYRINGE | 3500 IU | Solution for injection in pre-filled syringe · Parenteral use | 2 Pre-filled syringe | SAR 39.65 | Biological · Prescription | Hikma Pharmaceuticals PLC | Valid |
| HIBOR 5000 I.U. - 0.2 ML PREFILLED SYRINGE | 5000 IU | Solution for injection in pre-filled syringe · Parenteral use | 2 Pre-filled syringe | SAR 56.65 | Biological · Prescription | Hikma Pharmaceuticals PLC | Valid |
| HIBOR 7500 I.U. - 0.3 ML PREFILLED SYRINGE | 7500 IU | Solution for injection in pre-filled syringe · Parenteral use | 2 Pre-filled syringe | SAR 84.95 | Biological · Prescription | Hikma Pharmaceuticals PLC | Valid |
Indications — CHI Daman Drug Formulary
ANTIPHOSPHOLIPID SYNDROME; BARIATRIC SURGERY; CHRONIC LYMPHOCYTIC LEUKEMIA (CLL); DIALYSIS; DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); FOLLICULAR LYMPHOMA; HODGKIN'S LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; MYELOFIBROSIS-ADVERSE REACTION MANAGEMENT; T-CELL LYMPHOMA-RENAL TOXICITY
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.